Skip to content

Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts

Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02403206
Enrollment
406
Registered
2015-03-31
Start date
2015-03-26
Completion date
2016-08-24
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intumescent Cataract

Brief summary

The purpose of the study is to compare femtosecond laser-assisted capsulotomy to manual capsulorhexis in patients with intumescent cataracts. An intumescent cataract is defined as a cataract with a pressurized capsular bag.

Interventions

Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens

PROCEDUREContinuous Curvilinear Capsulorhexis (CCC)

Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery

Sponsors

Alcon, a Novartis Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing to undergo cataract surgery. * Able to lie flat in a supine position. * Able to understand and willing to sign the Informed Consent Form (ICF). * Presenting with intumescent white cataract, with a liquid pressurized bag and a milky, liquid cortex. * Other protocol-specified inclusion criteria may apply.

Exclusion criteria

* Pregnant or lactating mothers. * Corneal disease that precludes application of the cornea or transmission of laser light at 1030 nanometer (nm) wavelength. * Corneal opacity that would interfere with the laser beam. * Presence of blood or other material in the anterior chamber. * Hypotony or presence of corneal implant. * Poorly dilating pupils. * Condition which would cause inadequate clearance between the intended capsulotomy depth and the endothelium. * Residual, recurrent, active ocular or eye lid disease, including any corneal abnormality. * Any contraindication to cataract surgery. * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Capsular Tears (Anterior or Posterior) During SurgeryDay 0 (operative day)A capsular tear is defined as any unintended tear on the anterior or posterior capsule and includes a radial tear that moves peripherally on the anterior capsule during capsulotomy and extends to form a posterior capsular tear during intumescent cataract surgery. An intumescent cataract is defined as a cataract with a pressurized capsular bag. A lower value indicates fewer capsular tears. Only one eye (study eye) contributed to the analysis.

Secondary

MeasureTime frameDescription
Operating Time in the Eye to Complete Entire Cataract ProcedureDay 0 (operative day)Operating time in the eye was the time interval (in seconds) from the time the corneal incision was opened to the time the wound was closed. Only one eye (study eye) contributed to the analysis.

Participant flow

Recruitment details

Subjects were recruited from 14 investigative sites: 1 located in Greece, 4 located in India, 2 located in Mexico, 1 located in the Philippines, 3 located in Romania, and 3 located in the US.

Pre-assignment details

Of the 406 enrolled, 6 subjects were exited as screen failures and 10 withdrew prior to randomization. This reporting group includes all randomized subjects (390).

Participants by arm

ArmCount
Laser (LSX)
Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
187
Manual (CCC)
CCC performed during cataract surgery
189
Total376

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up43
Overall StudyPhysician Decision20
Overall StudyReason not given24
Overall StudyWithdrawal by Subject33

Baseline characteristics

CharacteristicLaser (LSX)Manual (CCC)Total
Age, Continuous64.9 years
STANDARD_DEVIATION 13.6
66.4 years
STANDARD_DEVIATION 11.9
65.6 years
STANDARD_DEVIATION 12.8
Sex: Female, Male
Female
110 Participants117 Participants227 Participants
Sex: Female, Male
Male
77 Participants72 Participants149 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 4060 / 1880 / 191
other
Total, other adverse events
0 / 40646 / 18843 / 191
serious
Total, serious adverse events
1 / 40616 / 18814 / 191

Outcome results

Primary

Percentage of Capsular Tears (Anterior or Posterior) During Surgery

A capsular tear is defined as any unintended tear on the anterior or posterior capsule and includes a radial tear that moves peripherally on the anterior capsule during capsulotomy and extends to form a posterior capsular tear during intumescent cataract surgery. An intumescent cataract is defined as a cataract with a pressurized capsular bag. A lower value indicates fewer capsular tears. Only one eye (study eye) contributed to the analysis.

Time frame: Day 0 (operative day)

Population: Intent-to-Treat Analysis Set

ArmMeasureValue (NUMBER)
Laser (LSX)Percentage of Capsular Tears (Anterior or Posterior) During Surgery5.3 percentage of capsular tears
Manual (CCC)Percentage of Capsular Tears (Anterior or Posterior) During Surgery5.3 percentage of capsular tears
Secondary

Operating Time in the Eye to Complete Entire Cataract Procedure

Operating time in the eye was the time interval (in seconds) from the time the corneal incision was opened to the time the wound was closed. Only one eye (study eye) contributed to the analysis.

Time frame: Day 0 (operative day)

Population: Intent-to-Treat Analysis Set

ArmMeasureValue (MEAN)Dispersion
Laser (LSX)Operating Time in the Eye to Complete Entire Cataract Procedure795.0 secondsStandard Deviation 354.7
Manual (CCC)Operating Time in the Eye to Complete Entire Cataract Procedure856.6 secondsStandard Deviation 436.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026